Sorting through the many opportunities for melanoma therapy

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Pigment Cell & Melanoma Research (Impact Factor: 4.62). 09/2011; 24(5):975-7. DOI: 10.1111/j.1755-148X.2011.00906.x
Source: PubMed
2 Reads
  • Source
    • "Treatment opportunities arise from a large portfolio of candidate drugs some of which have made it to clinical studies; however, with differing and often unpredictable outcomes. Thus the need for a better molecular understanding of melanomagenesis and preclinical studies in-vitro and in animal models is undisputed [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aberrations in gene expression are a hallmark of cancer cells. Differential tumor-specific transcript levels of single genes or whole sets of genes may be critical for the neoplastic phenotype and important for therapeutic considerations or useful as biomarkers. As an approach to filter out such relevant expression differences from the plethora of changes noted in global expression profiling studies, we searched for changes of gene expression levels that are conserved. Transcriptomes from massive parallel sequencing of different types of melanoma from medaka were generated and compared to microarray datasets from zebrafish and human melanoma. This revealed molecular conservation at various levels between fish models and human tumors providing a useful strategy for identifying expression signatures strongly associated with disease phenotypes and uncovering new melanoma molecules.
    PLoS ONE 05/2012; 7(5):e37880. DOI:10.1371/journal.pone.0037880 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor cell subpopulations that express cancer stem cell markers such as CD133 (prominin1) or ABCB5 are thought to be crucial for tumor initiation and heterogeneity, but their biological significance in melanoma has been controversial. Here, we report that CD133(+) and ABCB5(+) subpopulations are colocalized in melanomas in perivascular niches that contain CD144 (VE-cadherin)(+) melanoma cells forming vessel-like channels, a phenomenon termed vasculogenic mimicry (VM). RNAi-mediated attenuation of CD133 established its critical function in morphogenesis of these perivascular niches as well as in melanoma tumorigenicity. Niche-associated genes CD144 and ABCB5 were downregulated in tumors derived from CD133 knockdown (KD) melanoma cells compared with controls. CD133KD cells also lacked the ability to form CD144(+) VM-like channels in a manner that was associated with a depletion of the ABCB5(+) cell subpopulation. Finally, CD133 KD cells exhibited poorer tumor growth in vivo. Taken together, our findings corroborate models in which CD133(+)/ABCB5(+) melanoma cells reside in a complex anastomosing microvascular niche that encompasses CD144(+) VM channels as well as authentic endothelial cell-lined blood vessels. Further, they indicate that CD133(+) cells act as stem-like cells, which drive tumor growth by promoting VM and the morphogenesis of a specialized perivascular niche in melanoma. Cancer Res; 72(19); 5111-8. ©2012 AACR.
    Cancer Research 08/2012; 72(19):5111-8. DOI:10.1158/0008-5472.CAN-12-0624 · 9.33 Impact Factor